{"nctId":"NCT01363440","briefTitle":"Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","startDateStruct":{"date":"2011-05"},"conditions":["Diabetic Macular Edema"],"count":466,"armGroups":[{"label":"Macular Laser Photocoagulation Treatment (Control)","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Macular Laser Photocoagulation"]},{"label":"Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4","type":"EXPERIMENTAL","interventionNames":["Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)"]},{"label":"Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8","type":"EXPERIMENTAL","interventionNames":["Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)"]}],"interventions":[{"name":"Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)","otherNames":[]},{"name":"Macular Laser Photocoagulation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nThe following is an abbreviated list of inclusion criteria:\n\n* Adults ≥ 18 years with type 1 or 2 diabetes mellitus\n* Decrease in vision determined to be primarily the result of DME in the study eye\n* BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye\n\nExclusion Criteria:\n\nThe following is an abbreviated list of exclusion criteria:\n\n* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1\n* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1\n* Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1\n* Active proliferative diabetic retinopathy (PDR) in the study eye\n* Uncontrolled diabetes mellitus\n* Only 1 functional eye even if that eye is otherwise eligible for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)","description":"Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".10","spread":"1.03"},{"groupId":"OG001","value":"12.3","spread":".76"},{"groupId":"OG002","value":"10.6","spread":".69"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF","description":"Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.3","spread":"12.09"},{"groupId":"OG001","value":"-184.1","spread":"6.57"},{"groupId":"OG002","value":"-186.8","spread":"6.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF","description":"The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.55"},{"groupId":"OG001","value":"8.9","spread":"1.58"},{"groupId":"OG002","value":"8.1","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","description":"The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"1.44"},{"groupId":"OG001","value":"7.7","spread":"1.57"},{"groupId":"OG002","value":"6.5","spread":"1.48"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":67,"n":154},"commonTop":["Conjunctival haemorrhage","Hypertension","Conjunctival haemorrhage","Urinary tract infection","Diabetic retinal oedema"]}}}